The Emirates Drug Establishment has registered Foundayo, the oral form of Eli Lilly’s weight-loss drug orforglipron, making the United Arab Emirates the second country in the world to approve it, Gulf Business reported. The registration was completed on 3 April. The drug is expected to reach eligible patients from May, with the first supplies arriving in the opening week of the month. Metabolic, the Dubai clinic formerly known as GluCare.Health, said it would offer early access. That would make it the first provider outside the United States to do so.
Foundayo is a once-daily pill rather than an injection. Gulf Business reported that it is a small-molecule, non-peptide tablet taken without restrictions on food, water or timing. Its backers argue the format will suit patients who avoid needles or long injectable courses. In the trials Lilly has cited, participants on the highest dose lost an average of 12.4 per cent of their body weight when the drug was paired with lifestyle changes.
A drug approval, not yet a patient flow
The approval matters for medical tourism in a specific and limited way. A destination draws foreign patients by offering treatments they cannot easily get at home, and for a period the United Arab Emirates will be one of the few places outside the United States where orforglipron can be prescribed. The UAE has spent recent years selling that kind of edge, leaning on high healthcare-trust scores to court international patients, and Dubai has been building hospital capacity to match the pitch.
A daily tablet is a weaker travel driver than a procedure. A patient flies once for surgery and recovers on site, while a patient on orforglipron needs a prescription, monitoring and refills that a single trip does not settle. The registration is a supply signal, an announcement that the drug is legally available, rather than evidence that it is pulling arrivals. Whether the approval converts into foreign patient volume is a separate question, and it will show up in arrival figures rather than in the registration itself.
Metabolic frames the pill as maintenance
Metabolic has positioned Foundayo less as a first treatment than as a way to hold weight off after injectable therapy. Dr Ihsan Almarzooqi, the clinic’s co-founder and managing director, said obesity is “a complex metabolic disease, not a willpower issue or cosmetic concern,” and that most patients regain weight after intensive courses. Gulf Business reported that up to 70 per cent of patients regain weight after stopping GLP-1 drugs, and Metabolic said it uses microdosing and gradual dose reduction to slow that rebound.
The clinic cited its own 2025 outcomes report, Gulf Business reported. In it, 52.2 per cent of patients lost more than 10 per cent of their body weight over twelve months while preserving more muscle mass than standard care. Those figures come from the provider rather than an independent audit. They should be read as the clinic’s own account of its results. Metabolic said the model is certified by ICHOM, the body that sets outcome-measurement standards, and that it combines the drug with nutrition and behavioural support rather than a prescription alone.
The regulator’s speed is the real signal
Dr Fatima Al Kaabi, director-general of the Emirates Drug Establishment, said the approval showed the country’s intent to adopt new drugs quickly. She spoke to WAM, the state news agency cited by Gulf Business. Roberta Marinelli, president and general manager for Eli Lilly’s META hub, said the once-daily tablet gave people living with obesity an additional option. Gulf Business reported that health authorities tie obesity to type 2 diabetes, hypertension and several cancers, which is the case the establishment made for moving at speed.
The faster a regulator clears a drug that patients elsewhere cannot get, the sharper the destination’s temporary advantage, and orforglipron is registered as one of a small number of approvals the establishment has pushed through early. That advantage is short-lived by design, because other regulators approve the same drug in turn and the exclusivity window closes. A weight-loss pill also competes with itself once it travels, since a patient who can buy orforglipron at home has no reason to fly for it.
What operators should watch is narrow and dated. The checkable items are whether Foundayo actually reaches patients in the first week of May as scheduled, whether Metabolic stays the only provider outside the United States once supply widens, and whether any of this shows up as foreign patients booked for weight-management care rather than residents filling local prescriptions.
